Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High After Analyst Upgrade

Posted by Francis Steltz on Nov 12th, 2026

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) hit a new 52-week high on Thursday after Piper Sandler raised their price target on the stock from $44.00 to $56.00. Piper Sandler currently has an overweight rating on the stock. Teva Pharmaceutical Industries traded as high as $43.72 and last traded at $43.6740, with a volume of 77,497 shares changing hands. The stock had previously closed at $43.24.

TEVA has been the subject of a number of other research reports. Zacks Research cut Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 20th. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. TD Cowen raised their price objective on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. lifted their target price on Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Finally, HC Wainwright initiated coverage on Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a “buy” rating and a $52.00 target price on the stock. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $48.15.

Check Out Our Latest Report on Teva Pharmaceutical Industries

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total transaction of $14,358,456.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Sabag sold 46,000 shares of the stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the sale, the insider owned 80,760 shares of the company’s stock, valued at approximately $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 420,942 shares of company stock worth $16,572,473. 0.54% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently made changes to their positions in TEVA. Root Financial Partners LLC acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth approximately $33,000. Cornerstone Planning Group LLC lifted its stake in Teva Pharmaceutical Industries by 547.1% in the first quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after buying an additional 755 shares during the period. Western Wealth Management LLC acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $43,000. Sunbelt Securities Inc. acquired a new position in Teva Pharmaceutical Industries in the first quarter valued at approximately $45,000. Finally, CX Institutional bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth approximately $54,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

The stock has a market capitalization of $50.36 billion, a P/E ratio of 100.73, a PEG ratio of 3.97 and a beta of 0.97. The business has a fifty day simple moving average of $39.88 and a 200-day simple moving average of $34.96. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. During the same quarter in the prior year, the business earned $0.78 earnings per share. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current fiscal year.

Teva Pharmaceutical Industries Company Profile

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.